In the present study, we discovered the ability of CDK8/19i to sensitize CML cells to BCR-ABLi via prevention of BCR-ABLi-induced cell cycle arrest. This evidence concerns the gene CDK8 and chronic myelogenous leukemia, BCR-ABL1 positive.